GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
ILLUSTRATION 3 |MISSION AND STRATEGY
Our mission: One is to innovate. The other one is to differentiate. The other one is to accelerate and finally...
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List Within 30...
Corbus Pharma (CRBP) Explodes Higher After Reverse Split, up 1,288%!
From a Low of $2.11 Just Shy of a Year Ago, to an Intraday High of $29.30. A Ten Bagger in Less Than a...
Zivo Bioscience (ZIVO) Screams 2,608% Higher AFTER Reverse Split!
Okay, that's it. We are officially enamored with post reverse split trading!
First, there was our client, LQR House (LQR), then Polished (POL) and...
Top 10 AI Titans.
Delve into the pinnacle of AI innovation. This report is your guide to the seismic shifts in AI startups, the rise of ethical AI,...
Research Report: Society Pass (SOPA) $0.22. Price Target $4.00.
Three New Reports on Society Pass (SOPA) With Price Targets from $3.00 to $4.00.
(All Report Archive)
December 27th, 2023. Litchfield Hills Research – $4.00 Price...
Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.
Wall Street Cozy's up to Ardelyx After New Guidance.
On January 8th, Mike Raab, President and Chief Executive Officer stated, "We consistently grew sales of...
Is David Dodd on to his Next Billion Dollar Payday for Shareholders?
Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors.
GeoVax (GOVX) Completes Patient Enrollment for Head & Neck Cancer Drug, Gedeptin.®
David...
Happy New Year! Year End Charts.
Expect 2024 to be Year of Both Massive of Gains (and Losses) Plus Massive Volatility. Be Prepared!
2023 YEAR END CHARTS
Dow Jones Industrial Average
S&P 500
NASDAQ...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals,...
Latest article
Party Time at UniQure (QURE)! From $8.86 to $47.21, up 432%.
I. No Bells, No Baskets.UniQure (QURE) $47 up Huge. Still Not Out Of The Woods!II.Replimune (REPL) $11.23. Gains 28% in Sympathy with UniQure. We...
Adding Bavarian Nordic (BVRNY) $8.91, to Watch List.
Bavarian Nordic Lands $106 Million Contract for its Smallpox/Mpox Vaccine!
Were Back for the Third Time!
LIVE QUOTE
PREVIOUS WRITEUPS
Aug 27, 2025: Our 4th Billion Dollar Takeover!...
Fusion Energy Starter.
VC-Funded Fusion Energy Companies
"The fastest way to deploy fusion and I believe one of my forecasts is we will replace every coal and natural...
